European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer June 9, 2022June 27, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: CHMP recommends EU approval of Roche’s Tecentriq as…European Commission approves Roche’s Gavreto…European Commission approves Roche’s Tecentriq SC,…European Commission approves Roche’s first-in-class…European Commission approves label expansion of…Roche’s Polivy combination approved by European…
